Psychopharmacology

, Volume 124, Issue 1, pp 159–167

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

  • C. M. BeasleyJr
  • T. Sanger
  • W. Satterlee
  • G. Tollefson
  • P. Tran
  • S. Hamilton
Original Investigation

DOI: 10.1007/BF02245617

Cite this article as:
Beasley, C.M., Sanger, T., Satterlee, W. et al. Psychopharmacology (1996) 124: 159. doi:10.1007/BF02245617
  • 268 Views

Abstract

Olanzapine is a potential new “atypical” antipsychotic agent. This double-blind, acute phase study compared two doses of olanzapine [1 mg/day (Olz1.0); 10 mg/day (Olz10.0)] with placebo in the treatment of 152 patients who met the DSM-III-R criteria for schizophrenia and had a Brief Psychiatric Rating Scale (BPRS)-total score (items scored 0–6) ≥24. In overall symptomatology improvement [BPRS-total score and Positive and Negative Syndrome Scale (PANSS)-total score], Olz10.0 was statistically significantly superior to placebo. In positive symptom improvement (PANSS-positive score, BPRS-positive score), Olz10.0 was statistically significantly superior to placebo. In negative symptom improvement (PANSS-negative score), Olz10.0 was statistically superior to placebo. Olz 1.0 was clinically comparable to placebo in all efficacy comparisons. The only adverse event to show an overall statistically significant incidence difference was anorexia (reported for 10% of placebo-treated and 0% of Olz10.0-treated patients). The Olz10.0-treated patients improved over baseline with respect to parkinsonian and akathisia symptoms, and these changes were comparable with those observed with placebo. There were no dystonias associated with Olz10.0 treatment. At endpoint, the incidence of patients with elevated prolactin values did not differ statistically significantly between placebo-treated and Olz10.0-treated patients. Olanzapine appears to be not only safe and effective, but a promising atypical antipsychotic candidate.

Key words

OlanzapinePlaceboAcuteDouble-blindAtypicalSchizophreniaAntipsychotic

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • C. M. BeasleyJr
    • 1
  • T. Sanger
    • 1
  • W. Satterlee
    • 1
  • G. Tollefson
    • 1
  • P. Tran
    • 1
  • S. Hamilton
    • 1
  1. 1.Psychopharmacology Division, Lilly Research LaboratoriesEli Lilly and CompanyIndianapolisUSA